File T M, Tan J S
Northeastern Ohio Universities College of Medicine, Summa Health System, Akron, USA.
Am J Surg. 1995 May;169(5A Suppl):27S-33S.
Bacterial infections of the skin range from mild pyodermas to life-threatening necrotizing infections. Pyodermas are most often due to Staphylococcus aureus or beta-hemolytic Streptococcus sp, whereas infections associated with skin ulcers of the extremities, infections following trauma or surgery, and histotoxic necrotizing infections may involve a large number of additional pathogens, including Enterobacteriaceae, Pseudomonas sp, enterococci, and anaerobes. Management of bacterial skin and soft-tissue infections includes appropriate surgical drainage or excision of infected tissue and antimicrobial therapy. The combination of piperacillin and the beta-lactamase inhibitor tazobactam is a newly released antimicrobial, which has excellent in vitro activity against the vast majority of pathogens involved in skin infections. Two multicenter studies recently evaluated the efficacy and safety of piperacillin/tazobactam in the therapy of skin and soft-tissue infections in hospitalized patients. Piperacillin/tazobactam was well tolerated and demonstrated high clinical efficacy for the treatment of these infections.
皮肤细菌感染范围从轻度脓疱病到危及生命的坏死性感染。脓疱病最常见的病因是金黄色葡萄球菌或β溶血性链球菌，而与肢体皮肤溃疡相关的感染、创伤或手术后的感染以及组织毒性坏死性感染可能涉及大量其他病原体，包括肠杆菌科细菌、假单胞菌属、肠球菌和厌氧菌。细菌性皮肤和软组织感染的治疗包括对感染组织进行适当的手术引流或切除以及抗菌治疗。哌拉西林与β-内酰胺酶抑制剂他唑巴坦的联合制剂是一种新上市的抗菌药物，对绝大多数引起皮肤感染的病原体具有优异的体外活性。最近两项多中心研究评估了哌拉西林/他唑巴坦治疗住院患者皮肤和软组织感染的疗效和安全性。哌拉西林/他唑巴坦耐受性良好，对这些感染的治疗显示出高临床疗效。
